Compare PepsiCo, Inc. (PEP) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PepsiCo, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? PepsiCo, Inc. trades at $137.32 (market cap $186.57B), while State Street SPDR S&P Biotech ETF trades at $159.85. The key difference: PepsiCo, Inc. pays a 4.33% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, PepsiCo, Inc. nearer its low. Which is the better fit depends on your goals.
| PEP | XBI | |
|---|---|---|
Market Cap | $186.57B | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $170.44 | $169.55 |
52-Week Low | $134.95 | $93.43 |
Enterprise Value | $229.07B | — |
Dividend Yield | 4.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PepsiCo (PEP) trades at $138.45, up 0.6% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company maintains strong profitability with a 10.78% net margin and 51.59% ROE, though recent earnings beat expectations. Revenue grew to $93.93B in 2025, with a forward consensus price target of $158.79. Recent news highlights price cuts on snacks to address consumer pushback and a sponsorship withdrawal from a music festival.
The outlook is mixed: strong fundamentals and analyst buy ratings support upside, but technical bearishness and pricing strategy risks weigh. Investment appeal hinges on execution of North American turnaround and margin expansion. Key risks include competitive pressures and volatile cash flows. The stock offers a dividend yield near 4%, appealing for income-focused investors amid steady growth prospects.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
